NCT02921828 2022-07-05A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCelgeneCompleted1,149 enrolled
NCT01132833 2016-08-22Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving ChemotherapyUNC Lineberger Comprehensive Cancer CenterCompleted18 enrolled
NCT00378781 2012-02-24Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related InfectionM.D. Anderson Cancer CenterPhase NA Withdrawn